Trials / Completed
CompletedNCT04172987
A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants
Effect of Tirzepatide on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur will also be collected. Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 20 weeks, including screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| DRUG | EE/NGM | Combination oral contraceptive administered orally |
Timeline
- Start date
- 2020-02-26
- Primary completion
- 2021-02-09
- Completion
- 2021-02-09
- First posted
- 2019-11-21
- Last updated
- 2023-03-27
- Results posted
- 2023-03-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04172987. Inclusion in this directory is not an endorsement.